Dr. Darren Feldman on the Drawbacks of Dose Intensification for Advanced Germ Cell Tumors

Data from the phase 3 ENVISION trial demonstrate the potential of UGN-102 as an effective and durable nonsurgical treatment for patients with low-grade, intermediate-risk non–muscle-invasive bladder cancer.

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

Daniel Rubin, PharmD, BCOP, discussed a study showing how a clinical decision support tool can improve the documentation of biomarker results in cancer care.

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.

In an interview, Cedric Pobel, MD, further discussed the PEACE-1 trial and its findings.